FDA Approves Cobimetinib as Part of Drug Combination for Advanced Melanoma



The FDA has approved the targeted drug cobimetinib, in combination with another targeted therapy, to treat patients with advanced melanoma whose tumors have specific genetic mutations.



Source link

Comments are closed.